TL;DR
Researchers have identified a novel "dimer interface pocket" (DIP) on the androgen receptor (AR) and developed a small molecule, M17-B15, that targets this pocket to inhibit AR dimerization. This new strategy shows significant promise in combating prostate cancer, including drug-resistant forms, by disrupting a crucial step in AR signaling.
What Problem Does This Paper Address?
Prostate cancer (PCa) is heavily reliant on the androgen receptor (AR) for its growth and progression. Current AR-targeting drugs primarily work by blocking the AR's ligand-binding pocket (LBP). While effective initially, this approach often leads to drug resistance due to mutations in the AR, particularly within the LBP. This necessitates the development of new therapeutic strategies that target different aspects of AR function to overcome these resistance mechanisms and provide more effective treatments.
Methods
The study employed a multi-pronged approach:
- Molecular Dynamics (MD) Simulations: Used to explore the structural dynamics of the wild-type AR LBD and two AR LBD mutants associated with androgen insensitivity syndrome (AIS). This helped understand how mutations affect AR dimerization.
- Small-Angle X-ray Scattering (SAXS): Experimentally confirmed the structural changes observed in MD simulations, providing insights into the overall dimensions and shape of the AR LBD in solution, particularly regarding dimerization.
- Structure-Based Virtual Screening (SBVS): A computational method used to identify potential small molecules that could bind to a newly discovered pocket on the AR dimer interface. This involved filtering a large compound library based on drug-likeness (Lipinski's Rule of Five) and docking simulations.
- Structure-Activity Relationship (SAR) Exploration: A systematic chemical modification of initial hit compounds to optimize their potency and efficacy.
- Bioassays: A range of in vitro and in vivo experiments were conducted, including:
- AR Transcriptional Activity Assays: To measure the ability of compounds to inhibit AR-driven gene expression.
- Cell Viability Assays: To assess the impact of compounds on cancer cell proliferation.
- Competitive Ligand-Binding Assays: To confirm that the compounds do not bind to the LBP.
- Biolayer Interferometry (BLI): To measure direct binding affinity of compounds to AR LBD.
- Fluorescence Resonance Energy Transfer (FRET) Microscopy: To visualize and quantify AR dimerization in living cells.
- Mouse Xenograft Models: To evaluate the anti-tumor efficacy of the lead compound in vivo.
- RNA-sequencing (RNA-seq) and qPCR: To analyze gene expression changes induced by the compounds.
- Phylogenetic Analysis and Cross-Receptor Assays: To assess the selectivity of the developed compounds for AR over other nuclear receptors.
Datasets
- ChemDiv Database: A large library of approximately 1.6 million compounds was screened.
- AR LBD Structures: Wild-type and AIS-mutant AR LBD structures were used for MD simulations.
- Human Nuclear Receptor (NR) LBD Sequences: A dataset of 48 human NR LBD sequences was used for phylogenetic analysis and selectivity studies.
- Gene Expression Data: RNA-seq data from LNCaP cells treated with DHT, Enz, and M17-B15 were analyzed.
Key Insights and Ideas
- Dimerization as a Novel Target: The study highlights that disrupting AR dimerization, rather than just ligand binding, is a viable and potent strategy against prostate cancer. This opens up a new avenue for therapeutic development.
- Discovery of the Dimer Interface Pocket (DIP): A previously uncharacterized pocket at the AR dimer interface was identified, offering a new binding site for small-molecule inhibitors.
- AIS Mutations Inform Strategy: Gain-of-function mutations in AR associated with AIS, which destabilize AR dimerization, provided the crucial insight to target this interface.
- M17-B15 Selectivity: The developed compound M17-B15 demonstrates high selectivity for AR over other nuclear receptors (PR, GR, MR), suggesting a potentially favorable safety profile.
- Overcoming Resistance: M17-B15 shows efficacy against AR mutants (F876L and F876L/T877A) that confer resistance to existing drugs like enzalutamide, indicating its potential to treat resistant forms of PCa.
Key Results
- M17-B15 Potency: The optimized compound M17-B15 exhibits a potent AR transcriptional inhibition with an IC50 of 0.03 µM, representing a >31-fold improvement over the initial hit M17.
- AR Dimerization Inhibition: M17-B15 effectively disrupts AR LBD dimerization both in vitro (SAXS, BLI, CXMS) and in cellular FRET assays.
- Anti-Cancer Efficacy: M17-B15 significantly inhibits prostate cancer cell proliferation and PSA secretion in vitro.
- In Vivo Efficacy: In mouse xenograft models, M17-B15 demonstrated superior tumor growth inhibition (83.59%) compared to enzalutamide (51.35%) with no observed mortality or significant weight loss.
- Gene Expression Modulation: M17-B15 treatment led to a more specific gene expression profile compared to enzalutamide, with a significant downregulation of key genes associated with PCa progression.
Limitations and Future Work
- Pharmacokinetic Properties: The authors note that M17-B15 has poor solubility, limiting its oral and intravenous administration. Structural optimization is needed to improve its pharmacokinetic properties.
- Chemical Modification: Further chemical modification of the solvent-exposed moiety of M17-B15 is suggested to enhance its drug-like characteristics.
- Broader Therapeutic Applications: The study proposes that the DIP could inspire the development of new therapeutic modalities like PROTACs and molecular glues for PCa and other AR-related diseases.
- Variant NR Modulators: The DIP's potential as a target for developing variant NR modulators for other nuclear receptors is also highlighted.
Summary updated